Fate Therapeutics, Inc.

NasdaqGM:FATE Voorraadrapport

Marktkapitalisatie: US$276.7m

Fate Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Fate Therapeutics is J. Wolchko, benoemd in Dec2015, heeft een ambtstermijn van 8.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.52M, bestaande uit 18.3% salaris en 81.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.24% van de aandelen van het bedrijf, ter waarde $ 665.74K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 13.8 jaar.

Belangrijke informatie

J. Wolchko

Algemeen directeur

US$3.5m

Totale compensatie

Percentage CEO-salaris18.3%
Dienstverband CEO8.9yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn6.8yrs
Gemiddelde ambtstermijn bestuur13.8yrs

Recente managementupdates

Recent updates

Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Aug 21
Industry Analysts Just Made An Incredible Upgrade To Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Aug 11
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29

Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Apr 23
Fate Therapeutics, Inc.'s (NASDAQ:FATE) 28% Dip In Price Shows Sentiment Is Matching Revenues

Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Feb 16
Fate Therapeutics, Inc. (NASDAQ:FATE) Held Back By Insufficient Growth Even After Shares Climb 57%

Fate Therapeutics Update: A Rally Based On Little Increases Near-Term Risks

Jan 26

Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Dec 19
Fate Therapeutics, Inc.'s (NASDAQ:FATE) Shares Bounce 30% But Its Business Still Trails The Industry

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Deliver On Growth Plans?

Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Jun 07
Benign Growth For Fate Therapeutics, Inc. (NASDAQ:FATE) Underpins Its Share Price

Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

May 08
Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 41%

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Apr 17
Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Jan 10
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Sep 22
Here's Why We're Not Too Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Situation

Fate Therapeutics: Yes For Speculators, No For Defensive Investors

Aug 30

Needham initiates Fate coverage Therapeutics on potential of stem cell therapies

Jul 28

Fate Therapeutics names Brian Powl as chief commercial officer

Jun 30

Fate: Possible Speedy FDA Approval Process With RMAT Designation

Jun 03

We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Jun 02
We're Hopeful That Fate Therapeutics (NASDAQ:FATE) Will Use Its Cash Wisely

Fate Therapeutics: Slowly Getting To An Attractive Position

Feb 21

We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Feb 01
We're Not Very Worried About Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Analyse CEO-vergoeding

Hoe is J. Wolchko's beloning veranderd ten opzichte van Fate Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$176m

Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$4mUS$645k

-US$161m

Sep 30 2023n/an/a

-US$173m

Jun 30 2023n/an/a

-US$212m

Mar 31 2023n/an/a

-US$235m

Dec 31 2022US$8mUS$645k

-US$282m

Sep 30 2022n/an/a

-US$294m

Jun 30 2022n/an/a

-US$254m

Mar 31 2022n/an/a

-US$233m

Dec 31 2021US$12mUS$610k

-US$212m

Sep 30 2021n/an/a

-US$197m

Jun 30 2021n/an/a

-US$212m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$6mUS$570k

-US$173m

Sep 30 2020n/an/a

-US$149m

Jun 30 2020n/an/a

-US$117m

Mar 31 2020n/an/a

-US$112m

Dec 31 2019US$11mUS$540k

-US$98m

Sep 30 2019n/an/a

-US$86m

Jun 30 2019n/an/a

-US$76m

Mar 31 2019n/an/a

-US$72m

Dec 31 2018US$4mUS$516k

-US$67m

Sep 30 2018n/an/a

-US$63m

Jun 30 2018n/an/a

-US$57m

Mar 31 2018n/an/a

-US$47m

Dec 31 2017US$1mUS$480k

-US$43m

Compensatie versus markt: De totale vergoeding ($USD 3.52M ) J. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van J. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

J. Wolchko (54 yo)

8.9yrs

Tenure

US$3,522,750

Compensatie

Mr. J. Scott Wolchko is the Founder of Fate Therapeutics, Inc. and has been its Chief Executive Officer and President since December 1, 2015 & serves as It's CFO and CAO since June 3, 2024. Mr. Wolchko ser...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
J. Wolchko
Founder8.9yrsUS$3.52m0.24%
$ 665.7k
Cindy Tahl
Chief Legal & Compliance Officer and Corporate Secretary9.1yrsUS$2.82m0.053%
$ 146.4k
Bahram Valamehr
President of Research & Development6.8yrsUS$2.99m0.067%
$ 184.6k
Jerome Bressi
Chief Regulatory & Quality Officer2.8yrsgeen gegevens0.24%
$ 671.1k
Andrew Henry
Senior Vice President of Clinical Operationsless than a yeargeen gegevensgeen gegevens

6.8yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FATE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
J. Wolchko
Founder9.1yrsUS$3.52m0.24%
$ 665.7k
William Rastetter
Independent Chairman13yrsUS$253.25k0.54%
$ 1.5m
John Mendlein
Independent Vice Chairman of the Board16.6yrsUS$218.33k0.27%
$ 756.3k
Robert Langer
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Bennett Shapiro
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Robert Epstein
Independent Director10.7yrsUS$228.25k0.010%
$ 27.5k
Stuart Orkin
Member of Scientific Advisory Board14.5yrsgeen gegevensgeen gegevens
Sui Huang
Member of Scientific Advisory Board14.5yrsgeen gegevensgeen gegevens
Timothy Coughlin
Independent Director11.3yrsUS$231.75k0.058%
$ 161.1k
Sean Morrison
Member of Scientific Advisory Board14.5yrsgeen gegevensgeen gegevens
Mark Krasnow
Member of Scientific Advisory Board14.5yrsgeen gegevensgeen gegevens
Karin Jooss
Independent Director5.7yrsUS$227.82k0.0086%
$ 23.9k

13.8yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FATE zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.8 jaar).